Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
PNC27
An experimental p53-derived peptide studied for selective membrane disruption of cancer cells. Strictly preclinical; no approved or validated human use.
Contains an HDM-2-binding p53 domain fused to a membrane-residency peptide; reported to form transmembrane pores selectively in cancer cells in vitro.
In-vitro and limited animal studies from a small number of labs; results are not independently established and there are no human trials.
Typical Dose
No established human dose
Frequency
Varies
Route
SubQ
Notes
Experimental research compound.
Aggregated from 5 lab-verified Certificates of Analysis uploaded directly by labs. Purity averages exclude values outside [50%, 100%] to filter unit-misreads.
COAs
5
Verified labs
0
Avg purity
99.61%
±0.22%
Endotoxin tested
80%
This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.
Disclosed Labs